Abstract:Portal vein involvement is considered one of the most fearful complications of hepatocellular carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor biology (high grade), high tumor burden (number and size of lesions), high levels of serum markers (AFP), poor liver function (deranged LFT), and poor performance status of patients. The Barcelona Clinic Liver Cancer staging system places HCC patients with PVTT in advanced stage (BCLC Stage-C). This group contains a fairly heterogeneous patient population, previously considered candidates for palliative systemic therapy with sorafenib. However, this provided modest overall survival (OS) benefit. The results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib proved to be non-inferior against sorafenib in a phase III (REFLECT trial), regorafenib (RESORCE trial), ramucirumab (REACH-2), and cabozantinib (CELESTIAL) have been approved second-line therapy in phase III clinical trials. Recently, the data on the prospect of other modalities in the management of HCC with PVTT is mounting with favorable results. Targeting multiple pathways in the HCC cascade using a combination of drugs and other modalities such as RT, TACE, TARE, and HAIC appear effective for systemic and loco-regional control. The quest for the ideal combination therapy and the sequence set is still widely unanswered and prospective trials are lacking. With the armament of available therapeutic options and the advances and refinements in the delivery system, down-staging patients to make them eligible for curative resection has been reported. In a rapidly evolving treatment landscape, performing surgery when appropriate, in the form of LR and even LT to achieve cure does not seem farfetched. Likewise, adjuvant therapy and prompt management of the recurrences holds the key to prolong OS and DFS. This review discusses the management options of HCC patients with PVTT.

Recent Advances on the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy

Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus

Treatment Options for Portal Hypertension in the Era of Liver Transplantation

Reply to ‘how to Select Eligible Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus for Deceased Donor Liver Transplantation?’

Advances in Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

[Progress in Surgical Treatment of Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].

Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review

Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides

Efficacy of Different Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma

Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Comprehensive Management of Hepatocellular Carcinoma Complicated with Portal Vein or Bile Duct Tumor Thrombus

Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus

Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers